Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Free Cash Flow for 7 consecutive years, with -$46.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow fell 16.38% year-over-year to -$46.9 million; the trailing twelve-month figure through Jun 2026 stood at -$174.8 million (up 36.24% YoY), and the FY2025 full-year result was -$178.7 million, up 53.23% from the prior year.
• Free Cash Flow climbed to -$46.9 million in Q2 2026 per DNA's latest filing, from -$48.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$23.5 million in Q1 2022 and bottomed at -$130.2 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$72.1 million across 5 years, with a median of -$60.2 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow plunged 368.63% in 2023, then surged 73.35% in 2025.
• Over 5 years, Free Cash Flow stood at -$130.2 million in 2022, then surged by 52.93% to -$61.3 million in 2023, then climbed by 8.38% to -$56.1 million in 2024, then increased by 15.07% to -$47.7 million in 2025, then climbed by 1.66% to -$46.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$46.9 million, -$48.6 million, and -$47.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.